ViacomCBS Declares Quarterly Cash Dividend

NEW YORK--(BUSINESS WIRE)-- ViacomCBS Inc. (NASDAQ: VIAC; VIACA) today announced that its Board of Directors has declared a quarterly cash dividend of $0.24 per share on both its Class A and Class B common stock. The dividend will be payable on April 1, 2020 to stockholders of record at the close of business on March 16, 2020.

About ViacomCBS

ViacomCBS (NASDAQ: VIAC; VIACA) is a leading global media and entertainment company that creates premium content and experiences for audiences worldwide. Driven by iconic consumer brands, its portfolio includes CBS, Showtime Networks, Paramount Pictures, Nickelodeon, MTV, Comedy Central, BET, CBS All Access, Pluto TV and Simon & Schuster, among others. The company delivers the largest share of the U.S. television audience and boasts one of the industry’s most important and extensive libraries of TV and film titles. In addition to offering innovative streaming services and digital video products, ViacomCBS provides powerful capabilities in production, distribution and advertising solutions for partners on five continents.

For more information about ViacomCBS, please visit www.viacbs.com and follow @ViacomCBS on social platforms.

VIAC-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005851/en/

Press:
Justin Blaber
Senior Director, Corporate Communications
(212) 846-3139
[email protected]

Pranita Sookai
Director, Corporate Communications
(212) 846-7553
[email protected]

Investors:
Anthony DiClemente
Executive Vice President, Investor Relations
(212) 846-5208
[email protected]

Jaime Morris
Vice President, Investor Relations
(212) 846-5237
[email protected]

Source: ViacomCBS Inc.

You May Also Be Interested In

• HTEC and Embotech Partner to Scale Deployment of Autonomous Driving Solutions for Industrial Logistics
• Marimaca Copper Extends High-Grade Bornite Zone at Pampa Medina - 6m of 6.11% Cu and 24.0g/t Ag; 40m of 2.04% Cu and 11.1g/t Ag from SPRD-07
• Kurin, Inc. Extends Record Performance with Two Consecutive Quarters of Record Revenues Driven by Commercial Growth and Clinical Adoption